低分子量药物的研究进展  

Progress in Research on Low Molecular Weight Drugs

作　　者：刘冰 Liu Bing(School of Pharmacy,Guizhou University,Guiyang 550025;Guizhou Engineering Laboratory for Synthetic Drugs,Guiyang 550025,China)

机构地区：[1]贵州大学药学院,贵州贵阳550025 [2]贵州省合成药物工程实验室,贵州贵阳550025

出　　处：《广东化工》2023年第5期114-116,共3页Guangdong Chemical Industry

摘　　要：低分子量药物是当代药物化学实践中的重要组成部分,如今的药物研发却很容易将其忽略。为了研究近年来低分子量药物的最新进展,本文调查了最新批准的药物,提供了抗炎、神经退行性、抗肿瘤3种类型的低分子量药物的案例研究。这些药物结构大多与已知药物或者天然底物的结构相似,其结构优化的特点是以低分子量的药物为起始,在优化过程中仍保持其低分子量特性。Low molecular weight drugs are an important part of contemporary medicinal chemistry practice,but it is easy to ignore them in current drug development.In order to study the recent advances in low molecular weight drugs in recent years,this paper investigates the newly approved drugs and provides case studies of anti-inflammatory,neurodegenerative,and anti-tumor lead-like drugs.Most of these drug structures are similar in structure to known drugs or natural substrates,and their structural optimization is characterized by low molecular weight drugs starting from a low molecular weight during optimization.

关 键 词：低分子量药物 抗炎 神经退行性 抗肿瘤 研究进展 

分 类 号：R914[医药卫生—药物化学]